CA2095789A1 - Transdermal administration system for estradiol - Google Patents

Transdermal administration system for estradiol

Info

Publication number
CA2095789A1
CA2095789A1 CA002095789A CA2095789A CA2095789A1 CA 2095789 A1 CA2095789 A1 CA 2095789A1 CA 002095789 A CA002095789 A CA 002095789A CA 2095789 A CA2095789 A CA 2095789A CA 2095789 A1 CA2095789 A1 CA 2095789A1
Authority
CA
Canada
Prior art keywords
estradiol
adhesive
solvent
mixture
transdermal administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002095789A
Other languages
French (fr)
Other versions
CA2095789C (en
Inventor
Jacques Gonella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antares Pharma IPL AG
Original Assignee
Giapharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giapharma SA filed Critical Giapharma SA
Publication of CA2095789A1 publication Critical patent/CA2095789A1/en
Application granted granted Critical
Publication of CA2095789C publication Critical patent/CA2095789C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol

Abstract

The adhesive plaster for the transdermal ad-ministration of estradiol or mixture estradiol/ proges-tin is composed of an impermeable carrier film and of an adhesive composition. The latter represents a matrix or reservoir layer and is composed of a solvent-based polyacrylate or polyisobutylene adhesive which contains a saturated or unsaturated fatty acid with 6 to 18 C
atoms as permeability enhancer, estradiol or mixture estradiol/progestin as active substance and optionally propylene glycol as solvent.

The adhesive plaster is used for the systemic administration of hormones in hormone replacement ther-apy for a time of at least 3 days.
CA002095789A 1992-05-08 1993-05-07 Transdermal administration system for estradiol Expired - Fee Related CA2095789C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH148792 1992-05-08
CH1487/92 1992-05-08
US08/358,897 US5665377A (en) 1992-05-08 1994-12-19 Administration system for estradiol

Publications (2)

Publication Number Publication Date
CA2095789A1 true CA2095789A1 (en) 1993-11-09
CA2095789C CA2095789C (en) 2002-12-03

Family

ID=25687798

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002095789A Expired - Fee Related CA2095789C (en) 1992-05-08 1993-05-07 Transdermal administration system for estradiol

Country Status (11)

Country Link
US (1) US5665377A (en)
EP (1) EP0569338B1 (en)
JP (1) JP2960832B2 (en)
AT (1) ATE169213T1 (en)
AU (1) AU670273B2 (en)
CA (1) CA2095789C (en)
DE (1) DE69320096T2 (en)
DK (1) DK0569338T3 (en)
ES (1) ES2121975T3 (en)
NZ (1) NZ247549A (en)
ZA (1) ZA933180B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
DE4400770C1 (en) * 1994-01-13 1995-02-02 Lohmann Therapie Syst Lts Plaster containing an active substance for delivery of oestradiol with at least one penetration enhancer, method of producing it and its use
AU703593B2 (en) * 1995-06-07 1999-03-25 Ortho-Mcneil Pharmaceutical, Inc. Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US5910403A (en) * 1997-05-15 1999-06-08 The Regents Of University Of California Methods for measuring cellular proliferation and destruction rates in vitro and in vivo
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen
US6692763B1 (en) 1998-11-19 2004-02-17 The Regents Of The University Of California Methods for treating postmenopausal women using ultra-low doses of estrogen
FR2776191B1 (en) * 1998-03-23 2002-05-31 Theramex TOPICAL HORMONAL COMPOSITION WITH SYSTEMIC EFFECT
GB9828480D0 (en) * 1998-12-24 1999-02-17 Dermatech Limited Transdermal drug delivery system
WO2000053226A1 (en) * 1999-03-11 2000-09-14 Saitama Daiichi Pharmaceutical Co., Ltd. Compositions for promoting percutaneous absorption
DE10019171A1 (en) * 2000-04-07 2001-10-18 Schering Ag Compositions for use as penetration enhancers in transdermal formulations for highly lipophilic active ingredients
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
AU2002365268B2 (en) * 2001-10-24 2008-02-28 The Regents Of The University Of California Measurement of protein synthesis rates in humans and experimental systems by use of isotopically labeled water
DE10159120B4 (en) * 2001-12-01 2006-08-17 Lts Lohmann Therapie-Systeme Ag Steroid hormone-containing transdermal therapeutic systems containing propylene glycol monocaprylate and its use
US7449171B2 (en) * 2002-02-12 2008-11-11 The Regents Of The University Of California Measurement of biosynthesis and breakdown rates of biological molecules that are inaccessible or not easily accessible to direct sampling, non-invasively, by label incorporation into metabolic derivatives and catabolic products
CA2494715C (en) * 2002-07-30 2014-07-08 The Regents Of The University Of California Method for automated, large-scale measurement of the molecular flux rates using mass spectrometry
WO2004021863A2 (en) * 2002-09-04 2004-03-18 The Regents Of The University Of California Methods for measuring rates of replication and death of nfectious microbial agents in an infected host organism
DE60324950D1 (en) 2002-09-13 2009-01-08 Univ California METHOD OF MEASURING THE SPEEDS OF CHOLESTER REVERSE TRANSPORT IN VIVO AS AN INDEX FOR ANTI-ARTHEROGENESIS
US20070248540A1 (en) * 2002-09-16 2007-10-25 The Regents Of The University Of California Biochemical methods for measuring metabolic fitness of tissues or whole organisms
CA2504313C (en) * 2002-11-04 2012-01-17 Marc K. Hellerstein Deuterated glucose or fat tolerance tests for high-throughput measurement of the metabolism of sugars or fatty acids in the body
ES2536713T3 (en) 2003-03-12 2015-05-27 Epitome Pharmaceuticals Limited Compositions for lipophilic skin of rapid absorption and uses thereof
US7858607B2 (en) * 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
US7262020B2 (en) * 2003-07-03 2007-08-28 The Regents Of The University Of California Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
WO2005025549A2 (en) * 2003-09-10 2005-03-24 Noven Pharmaceuticals, Inc. Multi-layer transdermal drug delivery device
JP2007509951A (en) * 2003-10-28 2007-04-19 ノーヴェン ファーマシューティカルズ インコーポレイテッド Compositions and methods for controlling drug loss and delivery in transdermal drug delivery systems
US20050202406A1 (en) 2003-11-25 2005-09-15 The Regents Of The University Of California Method for high-throughput screening of compounds and combinations of compounds for discovery and quantification of actions, particularly unanticipated therapeutic or toxic actions, in biological systems
TW200538738A (en) 2004-02-20 2005-12-01 Univ California Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity
WO2005087943A1 (en) * 2004-03-11 2005-09-22 The Regents Of The University Of California Temporal or spatial characterization of biosynthetic events in living organisms by isotopic fingerprinting under conditions of imposed isotopic gradients
US20050238577A1 (en) * 2004-03-29 2005-10-27 The Regents Of The University Of California Isolation of epithelial cells or their biochemical contents from excreta after in vivo isotopic labeling
US8343538B2 (en) * 2004-10-08 2013-01-01 Noven Pharmaceuticals, Inc. Compositions and methods for controlling the flux of a drug from a transdermal drug delivery systems
US20060078602A1 (en) 2004-10-08 2006-04-13 Noven Pharmaceuticals, Inc. Device for transdermal administration of drugs including acrylic polymers
US20060251576A1 (en) * 2005-05-03 2006-11-09 The Regents Of The University Of California Methods for measuring cholesterol metabolism and transport
TW200711660A (en) 2005-06-10 2007-04-01 Univ California Monitoring two dimensions of diabetes pathogenesis separately or concurrently (insulin sensitivity and beta-cell sufficiency): uses in diagnosis, prognosis, assessment of disease risk, and drug development
AU2006299833B2 (en) 2005-10-12 2012-04-12 Besins Healthcare Luxembourg Sarl Improved testosterone gel and method of use
US8231906B2 (en) 2008-07-10 2012-07-31 Noven Pharmaceuticals, Inc. Transdermal estrogen device and delivery
US20130032163A1 (en) * 2011-08-03 2013-02-07 Nail Couture L.A. Llc System and method for nail foil application
WO2013036885A1 (en) 2011-09-08 2013-03-14 The Regents Of The University Of California Metabolic flux measurement, imaging and microscopy
ES2668678T3 (en) 2011-12-07 2018-05-21 Glaxosmithkline Llc Procedure for determining total body skeletal muscle mass
US9134319B2 (en) 2013-03-15 2015-09-15 The Regents Of The University Of California Method for replacing biomarkers of protein kinetics from tissue samples by biomarkers of protein kinetics from body fluids after isotopic labeling in vivo

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5843368B2 (en) * 1980-10-30 1983-09-27 日東電工株式会社 Anti-inflammatory analgesic patch
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4818540A (en) * 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US4764381A (en) * 1985-12-06 1988-08-16 Key Pharmaceuticals, Inc. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
US5145682A (en) * 1986-05-30 1992-09-08 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
ES2081823T3 (en) * 1988-10-27 1996-03-16 Schering Ag AGENT FOR TRANSDERMIC APPLICATION, CONTAINING GESTODEN.
CA2004203A1 (en) * 1988-12-01 1990-06-01 Sharad K. Govil Compositions for transdermal delivery of estradiol
DE3933460A1 (en) * 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts OSTROGEN-ACTIVE PLASTER
AR246186A1 (en) * 1989-11-17 1994-07-29 Beta Pharm Co Procedure for manufacturing a device for administering stradiol through the skin.
US5122382A (en) * 1990-10-29 1992-06-16 Alza Corporation Transdermal contraceptive formulations, methods and devices

Also Published As

Publication number Publication date
ATE169213T1 (en) 1998-08-15
ZA933180B (en) 1994-06-14
DK0569338T3 (en) 1999-05-03
DE69320096D1 (en) 1998-09-10
DE69320096T2 (en) 1998-12-10
EP0569338A1 (en) 1993-11-10
JPH0614986A (en) 1994-01-25
ES2121975T3 (en) 1998-12-16
NZ247549A (en) 1995-12-21
AU3845993A (en) 1993-11-11
US5665377A (en) 1997-09-09
AU670273B2 (en) 1996-07-11
EP0569338B1 (en) 1998-08-05
JP2960832B2 (en) 1999-10-12
CA2095789C (en) 2002-12-03

Similar Documents

Publication Publication Date Title
CA2095789A1 (en) Transdermal administration system for estradiol
US6149935A (en) Solid matrix system for transdermal drug delivery
US5904931A (en) Transdermal therapeutic systems that contain sex steroids and dimethyl isosorbide
KR100215027B1 (en) Composition for transdermal administration of steroid drugs and formulation containing same
ATA87488A (en) MULTI-LAYER TRANSDERMAL THERAPEUTIC SYSTEM FOR THE COMBINED APPLICATION OF OESTROGEN OR. SYNTHETIC EESTROGEN-ACTIVE COMPOUNDS WITH SYNTHETIC GESTAGENS
JP3821855B2 (en) Transdermal absorption therapy system for hormone supply
GB2212723A (en) Skin permeation enhancer compositions using glycerol monooleate
KR940013496A (en) Transdermal administration system
KR19990035795A (en) Hormone patch
CA2209711A1 (en) Plaster containing estradiol
RU99118582A (en) Composition for transdermal administration of steroid drugs
CA2453013A1 (en) Dermal, transdermal, mucosal or transmucosal ingredient delivery devices
PT96028A (en) 17- (CYCLOPROPYL-METHYL) -ALFA- (1,1-DIMETHYL-ETHYL) -4,5-EPOXY-18,19-DIHYDRO-3-HYDROXY-6-METHODS METHOXY-ALPHA-METHYL-6,14-ETENOMORFINANE-7-METHANOL (BUPRENORFINAL) AS ACTIVE INGREDIENT
JPH02157226A (en) Novel composition for increasing skin penetrability
CA2183544A1 (en) Desogestrel-containing transdermal application agent
JPS56140927A (en) Medical member
KR100229815B1 (en) Formulation for transdermal absorbent containing testosterone and preparation thereof
KR930023040A (en) Adhesive plaster for transdermal administration of estradiol and method for producing same
JP3002491B2 (en) Transdermal formulation
AU6879887A (en) Dermal and transdermal patches having a discontinuous pattern adhesive layer
CA2144441A1 (en) Dexpanthenol-containing plaster for the transdermal application of steroid hormones
CA2182188A1 (en) Agent, intended for transdermal administration, containing 14.alpha.,17.alpha.-ethanoestra-1,3,5(10)-triene-3,17.beta.-diol

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed